AnaptysBio, Inc.

NasdaqGS:ANAB.V Stock Report

Market Cap: US$2.0b

AnaptysBio Management

Management criteria checks 2/4

AnaptysBio's CEO is Dan Faga, appointed in Mar 2022, has a tenure of 4.08 years. total yearly compensation is $13.63M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 1.67% of the company’s shares, worth $33.60M. The average tenure of the management team and the board of directors is 5 years and 5.1 years respectively.

Key information

Dan Faga

Chief executive officer

US$13.6m

Total compensation

CEO salary percentage5.03%
CEO tenure4.1yrs
CEO ownership1.7%
Management average tenure5yrs
Board average tenure5.1yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Dan Faga's remuneration changed compared to AnaptysBio's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$13m

Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$133m

Mar 31 2025n/an/a

-US$141m

Dec 31 2024US$14mUS$685k

-US$145m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$170m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$7mUS$641k

-US$164m

Sep 30 2023n/an/a

-US$148m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$25mUS$474k

-US$129m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$108m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$310kn/a

-US$58m

Compensation vs Market: Dan's total compensation ($USD13.63M) is above average for companies of similar size in the US market ($USD5.34M).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan Faga (45 yo)

4.1yrs
Tenure
US$13,630,292
Compensation

Mr. Daniel R. Faga, also known as Dan, is President, CEO & Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21, 2022 to August 2023....

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Faga
President4.1yrsUS$13.63m1.67%
$ 33.6m
Dennis Mulroy
Chief Financial Officer5.8yrsUS$3.24m0.076%
$ 1.5m
Paul Lizzul
Chief Medical Officer5.8yrsUS$4.58m0.15%
$ 3.0m
Eric Loumeau
Chief Legal Officer7.7yrsUS$2.26m0.045%
$ 899.8k
Beth Mueller
Senior Vice President of Human Resources6.5yrsno datano data
Martin Dahl
Senior Vice President of Research4.3yrsno datano data
Benjamin Stone
Chief Business Officer2.3yrsno datano data
Monique Da Silva
Senior Vice President of Corporate Affairs2.3yrsno datano data
Priya Raina
Senior Vice President of Clinical Operations2.3yrsno datano data
Cailin Sibley
Senior Vice President of Translational Medicineno datano datano data
David McKeon
Senior VP & Controller7.2yrsno datano data
John Kwon
Vice President of GI Clinical Developmentno datano datano data
5.0yrs
Average Tenure
53yo
Average Age

Experienced Management: ANAB.V's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Faga
President4.4yrsUS$13.63m1.67%
$ 33.6m
John Orwin
Independent Chairman of the Board2.6yrsUS$456.69k0.037%
$ 747.7k
Hollings Renton
Lead Independent Director10.8yrsUS$426.69k0.017%
$ 348.0k
John Schmid
Independent Director10.8yrsUS$443.44k0.11%
$ 2.2m
Dennis Fenton
Independent Director8.1yrsUS$441.69k0.017%
$ 348.0k
Magda Marquet
Independent Director5.3yrsUS$426.69k0.035%
$ 696.1k
Oleg Nodelman
Independent Director5yrsno datano data
J. Ware
Independent Director8.7yrsUS$446.69k0.034%
$ 675.1k
Rita Jain
Independent Director3yrsUS$423.44k0.041%
$ 831.7k
Dolca Thomas
Member of Scientific Advisory Board3.3yrsno datano data
Luisa Salter-Cid
Member of Scientific Advisory Boardno datano datano data
John Monroe
Member of Scientific Advisory Boardno datano datano data
5.1yrs
Average Tenure
62yo
Average Age

Experienced Board: ANAB.V's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/12 12:06
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AnaptysBio, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Etzer DaroutBarclays
Michael KingCitizens JMP Securities, LLC